 NEW YORK, Nov. 2, 2020 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the company has enrolled and... 